Ligand Pharmaceuticals (LGNDZ) Research & Development (2016 - 2025)
Ligand Pharmaceuticals (LGNDZ) has disclosed Research & Development for 16 consecutive years, with $3.5 million as the latest value for Q4 2025.
- Quarterly Research & Development fell 20.66% to $3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $81.2 million through Dec 2025, up 278.91% year-over-year, with the annual reading at $81.2 million for FY2025, 278.91% up from the prior year.
- Research & Development hit $3.5 million in Q4 2025 for Ligand Pharmaceuticals, down from $21.0 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $50.1 million in Q1 2025 to a low of $3.5 million in Q4 2025.
- Historically, Research & Development has averaged $9.8 million across 5 years, with a median of $7.1 million in 2021.
- Biggest five-year swings in Research & Development: crashed 42.19% in 2021 and later skyrocketed 738.8% in 2025.
- Year by year, Research & Development stood at $8.1 million in 2021, then rose by 12.89% to $9.2 million in 2022, then plummeted by 40.33% to $5.5 million in 2023, then fell by 19.37% to $4.4 million in 2024, then decreased by 20.66% to $3.5 million in 2025.
- Business Quant data shows Research & Development for LGNDZ at $3.5 million in Q4 2025, $21.0 million in Q3 2025, and $6.6 million in Q2 2025.